{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:51:58Z","timestamp":1793379118096,"version":"4.5.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T00:00:00Z","timestamp":1449100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pharmaceutical antagonism of the mineralocorticoid receptor (MR) can protect against organ damage caused by elevated aldosterone levels in patients experiencing heart failure (HF), chronic kidney disease (CKD), primary aldosteronism, and hypertension. While traditional steroid-based MR antagonists effectively reduce mortality rates and extend patient survival, their broad application has been limited by significant side effects, most notably hyperkalaemia. Recently, finerenone (BAY 94-8862) has emerged as a next-generation non-steroidal dihydropyridine-based MR antagonist designed to minimize off-target effects while maintaining potent efficacy. In this review, the outcomes of finerenone therapy in several diseases associated with MR activity are explored. The (pre-) clinical efficacy of finerenone is compared with that of traditional steroid-based MR antagonists. Finally, recent and ongoing clinical trials using finerenone to treat chronic HF, CKD, and diabetic nephropathy are discussed. Taken together, pre-clinical and clinical evidence suggests that finerenone may achieve equivalent organ-protective effects with reduced levels of electrolyte disturbance compared with traditional steroid-based MR antagonists. This supports further clinical development of finerenone for the treatment of cardiovascular and renal disease.<\/jats:p>","DOI":"10.1002\/ejhf.444","type":"journal-article","created":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T20:31:28Z","timestamp":1449174688000},"page":"28-37","source":"Crossref","is-referenced-by-count":76,"title":["Non-Steroidal Mineralocorticoid Receptor Antagonism for the Treatment of Cardiovascular and Renal Disease"],"prefix":"10.1093","volume":"18","author":[{"given":"Peter","family":"Bramlage","sequence":"first","affiliation":[{"name":"Institute for Pharmacology and Preventive Medicine , Mahlow ,","place":["Germany"]},{"name":"Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Sevilla \u00a0","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Swift","sequence":"additional","affiliation":[{"name":"Institute for Pharmacology and Preventive Medicine , Mahlow ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Thoenes","sequence":"additional","affiliation":[{"name":"L\u00e9man Research Institute , Ober\u00e4geri ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Minguet","sequence":"additional","affiliation":[{"name":"Institute for Pharmacology and Preventive Medicine , Mahlow ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Ferrero","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Sevilla \u00a0","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland E.","family":"Schmieder","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, University Hospital of the University Erlangen-N\u00fcrnberg , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,12,3]]},"reference":[{"key":"2026011721133813000_ejhf444-bib-0001","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The role of renin\u2013angiotensin\u2013aldosterone system in the progression of chronic kidney disease","volume":"99","author":"Remuzzi","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"2026011721133813000_ejhf444-bib-0002","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","article-title":"Reconsidering the roles of the mineralocorticoid receptor","volume":"53","author":"Funder","year":"2009","journal-title":"Hypertension"},{"key":"2026011721133813000_ejhf444-bib-0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/joe.1.06017","article-title":"The new biology of aldosterone","volume":"186","author":"Connell","year":"2005","journal-title":"J Endocrinol"},{"key":"2026011721133813000_ejhf444-bib-0004","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.mce.2011.06.038","article-title":"Aldosterone, mineralocorticoid receptor, and heart failure","volume":"350","author":"Messaoudi","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"Suppl N","key":"2026011721133813000_ejhf444-bib-0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/eurheartj\/16.suppl_N.98","article-title":"Aldosterone and heart failure","volume":"16","author":"Zannad","year":"1995","journal-title":"Eur Heart J"},{"key":"2026011721133813000_ejhf444-bib-0006","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/HYPERTENSIONAHA.109.136242","article-title":"Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction","volume":"54","author":"Mihailidou","year":"2009","journal-title":"Hypertension"},{"key":"2026011721133813000_ejhf444-bib-0007","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.114.03311","article-title":"Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"64","author":"Deo","year":"2014","journal-title":"Hypertension"},{"key":"2026011721133813000_ejhf444-bib-0008","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jsbmb.2004.12.010","article-title":"RALES, EPHESUS and redox","volume":"93","author":"Funder","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2026011721133813000_ejhf444-bib-0009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JOE-11-0372","article-title":"Mechanisms of ligand specificity of the mineralocorticoid receptor","volume":"213","author":"Fuller","year":"2012","journal-title":"J Endocrinol"},{"key":"2026011721133813000_ejhf444-bib-0010","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026011721133813000_ejhf444-bib-0011","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026011721133813000_ejhf444-bib-0012","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/CIRCHEARTFAILURE.112.000003","article-title":"Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials","volume":"6","author":"Bapoje","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026011721133813000_ejhf444-bib-0013","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/bcp.12012","article-title":"Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis","volume":"75","author":"Hu","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2026011721133813000_ejhf444-bib-0014","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026011721133813000_ejhf444-bib-0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ejhf.30","article-title":"Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey","volume":"16","author":"van Deursen","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721133813000_ejhf444-bib-0016","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026011721133813000_ejhf444-bib-0017","article-title":"Spironolactone for hypertension","volume":"8","author":"Batterink","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2026011721133813000_ejhf444-bib-0018","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"2026011721133813000_ejhf444-bib-0019","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"2026011721133813000_ejhf444-bib-0020","first-page":"52","article-title":"Aldosterone antagonists in hypertension and heart failure","volume":"61","author":"Mantero","year":"2000","journal-title":"Ann Endocrinol (Paris)"},{"key":"2026011721133813000_ejhf444-bib-0021","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/01.HYP.0000036399.80194.D8","article-title":"Aldosterone antagonist improves diastolic function in essential hypertension","volume":"40","author":"Grandi","year":"2002","journal-title":"Hypertension"},{"key":"2026011721133813000_ejhf444-bib-0022","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011721133813000_ejhf444-bib-0023","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrcardio.2009.244","article-title":"Heart failure: aldosterone antagonists are underused by clinicians","volume":"7","author":"Samuel","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"2026011721133813000_ejhf444-bib-0024","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2026011721133813000_ejhf444-bib-0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011721133813000_ejhf444-bib-0026","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"2026011721133813000_ejhf444-bib-0027","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","article-title":"How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?","volume":"10","author":"Svensson","year":"2004","journal-title":"J Card Fail"},{"key":"2026011721133813000_ejhf444-bib-0028","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"key":"2026011721133813000_ejhf444-bib-0029","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","article-title":"Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases","volume":"110","author":"Schepkens","year":"2001","journal-title":"Am J Med"},{"key":"2026011721133813000_ejhf444-bib-0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.327.7407.147","article-title":"Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases","volume":"327","author":"Wrenger","year":"2003","journal-title":"BMJ"},{"key":"2026011721133813000_ejhf444-bib-0031","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"2026011721133813000_ejhf444-bib-0032","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721133813000_ejhf444-bib-0033","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1126\/science.289.5476.119","article-title":"Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy","volume":"289","author":"Geller","year":"2000","journal-title":"Science"},{"key":"2026011721133813000_ejhf444-bib-0034","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/me.2004-0537","article-title":"The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms","volume":"19","author":"Hultman","year":"2005","journal-title":"Mol Endocrinol"},{"key":"2026011721133813000_ejhf444-bib-0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721133813000_ejhf444-bib-0036","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1093\/eurheartj\/eht235","article-title":"The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects?","volume":"34","author":"Bauersachs","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721133813000_ejhf444-bib-0037","volume-title":"Fluorenone 1, 4,-Dihydropyridin Derivatives","author":"Ergueden","year":"2005"},{"key":"2026011721133813000_ejhf444-bib-0038","first-page":"13851","article-title":"Discovery of BAY 94\u20138862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"2026011721133813000_ejhf444-bib-0039","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"2026011721133813000_ejhf444-bib-0040","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1021\/jm1002827","article-title":"Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines","volume":"53","author":"Arhancet","year":"2010","journal-title":"J Med Chem"},{"key":"2026011721133813000_ejhf444-bib-0041","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","article-title":"A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity","volume":"51","author":"Dietz","year":"2008","journal-title":"Hypertension"},{"key":"2026011721133813000_ejhf444-bib-0042","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026011721133813000_ejhf444-bib-0043","article-title":"BAY 94\u20138862 exerts a potent natriuretic effect in healthy male subjects pre-treated with fludrocortisone: findings from a proof-of-concept study","volume":"126","author":"Lentini","year":"2012","journal-title":"Circulation"},{"key":"2026011721133813000_ejhf444-bib-0044","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis","volume":"10","author":"Sica","year":"2005","journal-title":"Heart Fail Rev"},{"key":"2026011721133813000_ejhf444-bib-0045","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1161\/hy09t1.095762","article-title":"Hyperkalemia, renal failure, and converting-enzyme inhibition: an overrated connection","volume":"38","author":"Garcia","year":"2001","journal-title":"Hypertension"},{"issue":"suppl 1","key":"2026011721133813000_ejhf444-bib-0046","first-page":"978","article-title":"Improved survival and nephroprotection in hypertensive rats by BAY 94\u20138862, a novel non-steroidal mineralocorticoid receptor antagonist","volume":"33","author":"Kolkhof","year":"2012","journal-title":"Eur Heart J"},{"key":"2026011721133813000_ejhf444-bib-0047","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.toxlet.2009.06.319","article-title":"Aldosterone causes DNA damage in vitro and in kidneys of DOCA\/salt rats, mediated by the mineralocorticoid receptor","volume":"189S","author":"Schupp","year":"2009","journal-title":"Toxicol Lett"},{"key":"2026011721133813000_ejhf444-bib-0048","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1479-5876-9-180","article-title":"The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism","volume":"9","author":"Eudy","year":"2011","journal-title":"J Transl Med"},{"key":"2026011721133813000_ejhf444-bib-0049","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","article-title":"Rationale and design of ARTS: a randomized, double-blind study of BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease","volume":"14","author":"Pitt","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011721133813000_ejhf444-bib-0050","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721133813000_ejhf444-bib-0051","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1161\/01.CIR.0000041661.63285.AE","article-title":"N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes","volume":"106","author":"Omland","year":"2002","journal-title":"Circulation"},{"key":"2026011721133813000_ejhf444-bib-0052","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1159\/000371497","article-title":"Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy","volume":"40","author":"Ruilope","year":"2014","journal-title":"Am J Nephrol"},{"key":"2026011721133813000_ejhf444-bib-0053","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2026011721133813000_ejhf444-bib-0054","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ejhf.218","article-title":"Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721133813000_ejhf444-bib-0055","volume-title":"Results of ARTS-HF: finerenone versus eplerenone in patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease","author":"Filippatos","year":"2015"},{"key":"2026011721133813000_ejhf444-bib-0056","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2003.10.008","article-title":"The 45-year story of the development of an anti-aldosterone more specific than spironolactone","volume":"217","author":"Menard","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"2026011721133813000_ejhf444-bib-0057","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1677\/JME-09-0031","article-title":"The mineralocorticoid receptor and its coregulators","volume":"43","author":"Yang","year":"2009","journal-title":"J Mol Endocrinol"},{"key":"2026011721133813000_ejhf444-bib-0058","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.semnephrol.2014.04.005","article-title":"Comparison of agents that affect aldosterone action","volume":"34","author":"Tamargo","year":"2014","journal-title":"Semin Nephrol"},{"key":"2026011721133813000_ejhf444-bib-0059","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1210\/jc.2003-032149","article-title":"Distinguishing the antihypertensive and electrolyte effects of eplerenone","volume":"89","author":"Levy","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2026011721133813000_ejhf444-bib-0060","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s40265-014-0306-5","article-title":"Updated national and international hypertension guidelines: a review of current recommendations","volume":"74","author":"Kjeldsen","year":"2014","journal-title":"Drugs"},{"key":"2026011721133813000_ejhf444-bib-0061","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1096\/fj.10-173286","article-title":"Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats","volume":"25","author":"Schupp","year":"2011","journal-title":"FASEB J"},{"key":"2026011721133813000_ejhf444-bib-0062","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1254\/jphs.10285FP","article-title":"SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na + excretion activity","volume":"115","author":"Nariai","year":"2011","journal-title":"J Pharmacol Sci"},{"key":"2026011721133813000_ejhf444-bib-0063","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000335559","article-title":"Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone\/salt-treated rats","volume":"89","author":"Nariai","year":"2012","journal-title":"Pharmacology"},{"key":"2026011721133813000_ejhf444-bib-0064","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm100505n","article-title":"Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g] indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy","volume":"53","author":"Meyers","year":"2010","journal-title":"J Med Chem"},{"key":"2026011721133813000_ejhf444-bib-0065","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphar.2013.00115","article-title":"PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy","volume":"4","author":"Orena","year":"2013","journal-title":"Front Pharmacol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.444","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/1\/28\/66383706\/eurjhf_18_1_28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/1\/28\/66383706\/eurjhf_18_1_28.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:13:57Z","timestamp":1768702437000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/18\/1\/28\/8423569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,3]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,3]]},"published-print":{"date-parts":[[2016,1,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.444","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725989934.793514779","asserted-by":"object"}]},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,1]]},"published":{"date-parts":[[2015,12,3]]}}}